Treatment using engineered T cells targeting MAGE-A4 in advanced solid tumors

A Single-arm, Open-label, Dose Exploratory Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Autologous Humanized MAGE-A4-directed T Cell Receptor Engineered T Cell (JWTCR001) in Patients With Advanced Solid Tumors

This study is testing a new treatment using specially engineered T cells to see if it can help people with advanced solid tumors that express a specific protein called MAGE-A4 after their previous treatments have not worked.

Quick facts

• Phase: PHASE1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Peking University (other)
• Locations: 1 site (Beijing, Beijing Municipality)
• Trial ID: NCT06170294 on ClinicalTrials.gov

What this trial studies

This is a single-arm, open-label study designed to explore the safety, efficacy, and pharmacokinetics of T cell receptor-engineered T cells (TCR-T) that specifically target the melanoma-associated antigen-4 (MAGE-A4) in patients with advanced solid tumors. Participants will be those who have shown progression after at least one prior treatment and have tumors expressing MAGE-A4. The study will involve dose escalation to determine the optimal regimen while monitoring for adverse effects and preliminary efficacy outcomes.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-75 with advanced solid tumors expressing MAGE-A4 who have not responded to previous treatments.

Not a fit: Patients with tumors that do not express MAGE-A4 or those who have not had prior systemic treatment may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could provide a novel treatment option for patients with advanced solid tumors that are currently refractory to standard therapies.

How similar studies have performed: While there have been studies exploring TCR-T therapies, this specific targeting of MAGE-A4 in advanced solid tumors represents a novel approach.

Eligibility criteria

Inclusion Criteria:

1. 18-75 year-old, male or female
2. Voluntarily willing to participate in the study and sign the written informed consent form
3. Life expectation ≥12 weeks
4. European Cooperative Oncology Group (ECOG) ≤1 at screening, 24 hours prior to apheresis (APH), lymphodepletion (LD), and infusion
5. Histologically-confirmed recurrent/metastatic advanced solid tumors
6. Radiologically-confirmed progression disease after at least one prior line of systematic treatment and no available standard of care at screening, judged by investigators
7. Fresh or formalin-fixed paraffin-embedded (FFPE) samples, immunohistochemistry (IHC)-stained MAGE-A4 positive
8. Human leukocyte antigen (HLA)-A\*02 allele matched
9. Per response evaluation criteria in solid tumors (RECIST) version 1.1, at least one measurable lesion
10. Adequate organ functions
11. Adequate venous access for APH
12. Non-hematological adverse events induced by previous treatment must have recovered to Grade ≤1 according to Common Terminology Criteria for Adverse Events (CTCAE), except for alopecia and peripheral neuropathy
13. Women of childbearing potential must agree to use an effective and reliable contraceptive method during 28 days prior to lymphodepletion to 1 year post infusion; Male patients who have not undergone vasectomy and have sexual activity with women of childbearing potential must agree to the use of a barrier contraceptive method since lymphodepletion to 1 year post infusion, and sperm donation is prohibited during the study
14. Women of childbearing potential must have negative serum human chorionic gonadotropin β (β-hCG) test result at screening and 48 hours prior to lymphodepletion

Exclusion Criteria:

1. Pregnant or lactating women
2. Human immunodeficiency virus (HIV) serology positive, or active hepatitis B virus (HBV)/hepatitis C virus (HCV)/Syphilis/Tuberculosis/ Coronavirus disease 2019 (COVID-19)
3. Central nerve system (CNS) metastasis must have received treatment and been neurologically stable for ≥2 months, not requiring anti-seizure medications and off steroids for ≥ 1 month prior to APH
4. Another primary malignancy within 3 years (with some exceptions for completely-resected early-stage tumors)
5. Subjects with extensive metastases, or more rapid tumor progression prior to lymphodepletion in comparison to screening, etc. which might not be appropriate for further study treatment judged by the investigators
6. Systematic autoimmune disorders requiring long-term systematic treatment
7. Previously treated with any genetically engineered modified T cell therapy or other cell and gene therapy (CGT)
8. History of organ transplant
9. Uncontrolled or active infection within 72 hours prior to screening, APH, LD, or within 5 days prior to infusion
10. Subjects with other serious diseases that may restrict them from participating in this study
11. Clinically significant CNS disorders, such as epilepsy, stroke, Parkinson disease, etc
12. Grade ≥ 2 hemorrhage within 30 days prior to screening, or in need of longterm anticoagulants
13. Active digestive ulcer or gastrointestinal (GI) bleeding within 3 months prior to screening
14. Not satisfying wash-out period for APH
15. Previously allergic or intolerable to JWTCR001 or its components
16. Unable or unwilling to comply with the study protocol, judged by the investigators
17. Other situations implying that the subject might not be appropriate to participate in the study

Where this trial is running

Beijing, Beijing Municipality

• Department of GI Oncology,Peking University Cancer Hospital — Beijing, Beijing Municipality, China (RECRUITING)

Study contacts

• Principal investigator: Lin Shen — Peking University Cancer Hospital & Institute
• Study coordinator: Lin Shen

Conditions: Advanced Solid Tumor